Bank of Nova Scotia
SRPT icon

Bank of Nova Scotia’s Sarepta Therapeutics SRPT Stock Holding History

Bank of Nova Scotia’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-228,731
Closed -$3.91M – 1116
2025
Q2 		$3.91M Buy
+228,731
New +$9.76M 0.01% 554
2025
Q1 		– Sell
-67,666
Closed -$8.23M – 1114
2024
Q4 		$8.23M Sell
67,666
-185,102
-73% -$22.7M 0.01% 449
2024
Q3 		$31.6M Sell
252,768
-57
-0% -$7.88K 0.06% 184
2024
Q2 		$39.9M Sell
252,825
-168,711
-40% -$21.7M 0.08% 175
2024
Q1 		$54.6M Sell
421,536
-107,257
-20% -$13.1M 0.11% 148
2023
Q4 		$51M Buy
+528,793
New +$50.7M 0.1% 162
2022
Q4 		– Sell
-14,000
Closed -$1.55M – 1239
2022
Q3 		$1.55M Sell
14,000
-124,000
-90% -$12.5M ﹤0.01% 705
2022
Q2 		$10.3M Buy
138,000
+10,000
+8% +$736K 0.02% 365
2022
Q1 		$10M Buy
128,000
+115,777
+947% +$8.87M 0.02% 452
2021
Q4 		$1.1M Sell
12,223
-196,895
-94% -$16.8M ﹤0.01% 970
2021
Q3 		$19.3M Buy
209,118
+202,759
+3,189% +$15.6M 0.03% 365
2021
Q2 		$494K Buy
+6,359
New +$482K ﹤0.01% 986
2020
Q4 		– Sell
-65,098
Closed -$9.14M – 1058
2020
Q3 		$9.14M Buy
65,098
+35,922
+123% +$5.46M 0.02% 374
2020
Q2 		$4.68M Buy
+29,176
New +$3.97M 0.02% 429
2019
Q4 		– Sell
-64,392
Closed -$4.85M – 981
2019
Q3 		$4.85M Buy
64,392
+58,117
+926% +$6.86M 0.01% 500
2019
Q2 		$954K Sell
6,275
-1,725
-22% -$210K ﹤0.01% 712
2019
Q1 		$954K Sell
8,000
-18,000
-69% -$2.31M ﹤0.01% 717
2018
Q4 		$2.84M Buy
+26,000
New +$3.25M 0.01% 520
2018
Q2 		– Sell
-24,700
Closed -$1.83M – 941
2018
Q1 		$1.83M Buy
+24,700
New +$1.65M 0.01% 592
2017
Q4 		– Sell
-121,767
Closed -$5.52M – 966
2017
Q3 		$5.52M Buy
+121,767
New +$4.87M 0.03% 353

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Bank of Nova Scotia's SRPT Position: Q3 2025 in Review

Bank of Nova Scotia sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 228,731 shares — an estimated $3.91M sold.

Bank of Nova Scotia first reported a position in SRPT in Q3 2017 and held it in 20 quarters. The position peaked at $54.6M in Q1 2024. 320 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • Bank of Nova Scotia reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Bank of Nova Scotia sold 228,731 Sarepta Therapeutics shares in Q3 2025, an estimated $3.91M.
  • Bank of Nova Scotia first reported a position in Sarepta Therapeutics in Q3 2017 and held it in 20 quarters.
  • Bank of Nova Scotia's Sarepta Therapeutics position peaked at $54.6M in Q1 2024.
  • 320 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Bank of Nova Scotia's 13F filing for Q3 2025, filed 14 Nov 2025.